Actemra gets advisory committee review
Executive Summary
Roche's Actemra (tocilizumab) will be evaluated by FDA's Arthritis Drugs Advisory Committee July 29. The rheumatoid arthritis candidate has a September user fee date, and if approved would be the first interleukin-6 receptor inhibitor approved for treatment of moderately to severely active rheumatoid arthritis in adults. Roche is seeking approval as monotherapy and in combination with disease-altering antirheumatic drugs
You may also be interested in...
PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports
France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.
Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
US Businessman Ignores Federal, State Regulators’ Warnings, Faces Criminal COVID-19 Fraud Charges
Federal prosecutors’ latest criminal case alleging fraudulent advertising and sales of vitamins and other nutrients available nonprescription in the US as remedies for infections from the novel coronavirus is against Johnny Stine, owner and operator of North Coast Biologics in Seattle.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: